Karyopharm Therapeutics Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Karyopharm Therapeutics Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Karyopharm Therapeutics Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $412M, a 8.62% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $412M +$32.7M +8.62% Dec 31, 2023 10-K 2024-02-29
Q4 2022 $379M +$48.3M +14.6% Dec 31, 2022 10-K 2024-02-29
Q4 2021 $331M +$55.5M +20.2% Dec 31, 2021 10-K 2023-02-17
Q4 2020 $275M +$50.4M +22.4% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $225M +$51.7M +29.8% Dec 31, 2019 10-K 2021-02-24
Q4 2018 $173M +$39.2M +29.2% Dec 31, 2018 10-K 2020-02-26
Q4 2017 $134M +$3.77M +2.89% Dec 31, 2017 10-K 2019-02-28
Q4 2016 $130M +$27.5M +26.8% Dec 31, 2016 10-K 2018-03-15
Q4 2015 $103M +$46.5M +82.7% Dec 31, 2015 10-K 2017-03-16
Q4 2014 $56.3M +$31.2M +124% Dec 31, 2014 10-K 2016-03-15
Q4 2013 $25.1M +$13.3M +112% Dec 31, 2013 10-K 2015-03-13
Q4 2012 $11.8M Dec 31, 2012 10-K 2014-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.